News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
579,816 Results
Type
Article (39668)
Company Profile (86)
Press Release (540061)
Multimedia
Podcasts (101)
Webinars (16)
Section
Business (174787)
Career Advice (2184)
Deals (28777)
Drug Delivery (90)
Drug Development (62026)
Employer Resources (148)
FDA (14016)
Job Trends (12643)
News (285999)
Policy (27195)
Tag
Academia (2200)
Academic (1)
Accelerated approval (11)
Adcomms (19)
Allergies (85)
Alliances (45163)
ALS (98)
Alzheimer's disease (1265)
Antibody-drug conjugate (ADC) (119)
Approvals (14040)
Artificial intelligence (305)
Autoimmune disease (25)
Automation (19)
Bankruptcy (268)
Best Places to Work (9938)
BIOSECURE Act (14)
Biosimilars (99)
Biotechnology (62)
Bladder cancer (79)
Brain cancer (27)
Breast cancer (323)
Cancer (2499)
Cardiovascular disease (192)
Career advice (1850)
Career pathing (27)
CAR-T (161)
CDC (43)
Cell therapy (455)
Cervical cancer (19)
Clinical research (50574)
Collaboration (956)
Company closure (3)
Compensation (351)
Complete response letters (14)
COVID-19 (2705)
CRISPR (53)
C-suite (310)
Cystic fibrosis (88)
Data (2606)
Decentralized trials (2)
Denatured (29)
Depression (59)
Diabetes (297)
Diagnostics (6599)
Digital health (18)
Diversity (4)
Diversity, equity & inclusion (43)
Drug discovery (130)
Drug pricing (110)
Drug shortages (27)
Duchenne muscular dystrophy (125)
Earnings (74570)
Editorial (46)
Employer branding (20)
Employer resources (134)
Events (87092)
Executive appointments (742)
FDA (15503)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (1)
Frontotemporal dementia (9)
Funding (798)
Gene editing (106)
Generative AI (29)
Gene therapy (351)
GLP-1 (681)
Government (4079)
Grass and pollen (5)
Guidances (202)
Healthcare (15546)
HIV (38)
Huntington's disease (21)
IgA nephropathy (31)
Immunology and inflammation (136)
Immuno-oncology (8)
Indications (37)
Infectious disease (2893)
Inflammatory bowel disease (124)
Inflation Reduction Act (11)
Influenza (74)
Intellectual property (96)
Interviews (397)
IPO (13105)
IRA (42)
Job creations (3085)
Job search strategy (1549)
Kidney cancer (10)
Labor market (44)
Layoffs (432)
Leadership (22)
Legal (6740)
Liver cancer (62)
Longevity (10)
Lung cancer (342)
Lymphoma (178)
Machine learning (8)
Management (51)
Manufacturing (368)
MASH (81)
Medical device (10762)
Medtech (10767)
Mergers & acquisitions (16298)
Metabolic disorders (707)
Multiple sclerosis (86)
NASH (15)
Neurodegenerative disease (117)
Neuropsychiatric disorders (30)
Neuroscience (1853)
NextGen: Class of 2025 (5269)
Non-profit (3807)
Now hiring (25)
Obesity (340)
Opinion (249)
Ovarian cancer (92)
Pain (88)
Pancreatic cancer (102)
Parkinson's disease (149)
Partnered (19)
Patents (255)
Patient recruitment (131)
Peanut (42)
People (48200)
Pharmaceutical (21)
Pharmacy benefit managers (15)
Phase I (15545)
Phase II (21791)
Phase III (17566)
Pipeline (1594)
Policy (204)
Postmarket research (2181)
Preclinical (6636)
Press Release (70)
Prostate cancer (148)
Psychedelics (30)
Radiopharmaceuticals (241)
Rare diseases (404)
Real estate (4869)
Recruiting (58)
Regulatory (18647)
Reports (37)
Research institute (2012)
Resumes & cover letters (337)
Rett syndrome (9)
RNA editing (9)
RSV (61)
Schizophrenia (82)
Series A (134)
Series B (90)
Service/supplier (6)
Sickle cell disease (54)
Special edition (18)
Spinal muscular atrophy (122)
Sponsored (33)
Startups (2890)
State (1)
Stomach cancer (12)
Supply chain (61)
Tariffs (55)
The Weekly (70)
Vaccines (930)
Venture capital (45)
Weight loss (210)
Women's health (36)
Worklife (16)
Date
Today (113)
Last 7 days (459)
Last 30 days (1508)
Last 365 days (25832)
2025 (14999)
2024 (28638)
2023 (32567)
2022 (42848)
2021 (46331)
2020 (45275)
2019 (38438)
2018 (28967)
2017 (27347)
2016 (26755)
2015 (31393)
2014 (25870)
2013 (22256)
2012 (22969)
2011 (23242)
2010 (21835)
Location
Africa (843)
Alabama (60)
Alaska (6)
Arizona (179)
Arkansas (9)
Asia (33149)
Australia (5757)
California (5962)
Canada (1966)
China (516)
Colorado (281)
Connecticut (297)
Delaware (159)
Europe (78813)
Florida (958)
Georgia (217)
Idaho (43)
Illinois (512)
India (30)
Indiana (304)
Iowa (15)
Japan (218)
Kansas (89)
Kentucky (26)
Louisiana (10)
Maine (70)
Maryland (876)
Massachusetts (4475)
Michigan (246)
Minnesota (344)
Mississippi (3)
Missouri (78)
Montana (26)
Nebraska (21)
Nevada (74)
New Hampshire (55)
New Jersey (1843)
New Mexico (27)
New York (1719)
North Carolina (937)
North Dakota (9)
Northern California (2654)
Ohio (202)
Oklahoma (15)
Oregon (25)
Pennsylvania (1279)
Puerto Rico (4)
Rhode Island (29)
South America (1059)
South Carolina (30)
Southern California (2255)
Tennessee (106)
Texas (944)
United States (22808)
Utah (197)
Virginia (162)
Washington D.C. (64)
Washington State (508)
West Virginia (4)
Wisconsin (68)
579,816 Results for "chiron corporation now novartis vaccines and diagnostics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Legal
BioNTech Attacked CureVac’s ‘Failed’ COVID Vaccine Program. The Rivals Are Now Merging
BioNTech said in 2022 that it faced “threats of a groundless patent infringement suit” from a company that was “unable to bring to market any product to help in the fight against COVID-19.” Now, the mRNA biotech is buying that very company.
June 18, 2025
·
4 min read
·
Nick Paul Taylor
Vaccines
After Moderna Pulled Its Shot, Combination Flu/COVID Vaccines Hang in Limbo
Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based combination shot that targets both influenza and COVID-19. Now, the entire vaccine sector is sizing up a new regulatory world, companies’ next steps uncertain.
July 21, 2025
·
7 min read
·
Dan Samorodnitsky
I&I
Novartis Drops up to $1B+ for Drug Discovery Deal With Matchpoint
The partnership with Matchpoint Therapeutics gets Novartis global rights on all molecules for several unannounced inflammatory diseases identified through the biotech’s discovery platform.
July 24, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
Longhorn Vaccines and Diagnostics Partners with Promega to Combine Complementary Offerings for Enhanced Sample Collection, Transport and Analysis
July 29, 2025
·
4 min read
Tariffs
Novartis ‘Moving as Fast as Possible’ to Fully Manufacture Key Drugs in US as Tariffs Near
In its Q2 earnings call Thursday, Novartis said it is moving quickly to reshore its drug manufacturing operations, but CEO Vas Narasimhan told reporters that for most medicines, it typically takes three to four years to completely relocate production.
July 17, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Wisp Launches New Diagnostics Vertical, Now Offers 360-Degree Telehealth Capabilities
May 28, 2025
·
3 min read
Immunology and inflammation
Late-Stage Stumble for Cosentyx Sets Novartis Back in Autoimmune Condition
Novartis is falling farther behind AbbVie, which expanded its JAK inhibitor Rinvoq into giant cell arteritis in April.
July 3, 2025
·
2 min read
·
Tristan Manalac
Legal
Former Chinook Board Member Indicted for Insider Trading Related to $3.2B Novartis Buy
Rouzbeh Haghighat was serving on the board of Chinook Therapeutics at the time of the Novartis acquisition and, according to the DOJ’s allegations, used confidential information to conduct insider trading.
May 28, 2025
·
2 min read
·
Tristan Manalac
Cardiovascular disease
Novartis Makes Potential $750M+ Bet Per Cardiovascular Disease Target in Another Flagship Pact
Flagship Pioneering’s ProFound Therapeutics will use its proprietary technology to mine the expanded proteome for novel cardiovascular therapeutics. Novartis has promised to pay up to $750 million per target, though it has not specified how many targets it will go after.
June 26, 2025
·
2 min read
·
Tristan Manalac
Rare diseases
Novartis’ Fabhalta Approved as First Therapy for Rare Kidney Disease
This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal hemoglobinuria and primary immunoglobulin A nephropathy.
March 21, 2025
·
2 min read
·
Dan Samorodnitsky
1 of 57,982
Next
